|
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes |
Jun 2023 |
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment |
Jan 2020 |
European Journal of Haematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study |
Jun 2023 |
European Journal of Haematology |
Aplastic Anemia |
|
Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro |
May 2020 |
Experimental Hematology |
Myelodysplastic Syndromes (MDS) |
|
Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro |
Jun 2020 |
Experimental Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review |
Jul 2023 |
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
|
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies |
Mar 2024 |
Expert Opinion on Biological Therapy |
Myelodysplastic Syndromes (MDS) |
|
Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
Oct 2024 |
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress |
Jul 2023 |
Expert Review of Anticancer Therapies |
Myelodysplastic Syndromes (MDS) |
|
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
Nov 2024 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
